Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIPER-101
- Development stage
- Phase 1
- Lead developer
- Vittoria Biotherapeutics
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VIPER-101 is a gene-edited, autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory T-cell lymphoma. It is engineered to target CD5, a surface glycoprotein present on cancer cells in over 85% of patients with T-cell lymphoma. The therapy utilizes Vittoria Biotherapeutics' proprietary Senza5 platform, which integrates CD5 gene-editing technology and a rapid five-day manufacturing process to enhance cell potency and stemness. By knocking out CD5 in the CAR-T cells, VIPER-101 circumvents fratricide (self-killing among therapeutic T-cells) and abrogates immunosuppressive signaling mediated by CD5, thereby improving anti-tumor efficacy and safety compared to conventional CAR-T therapies targeting T-cell malignancies. The drug is currently being evaluated in Phase 1 clinical trials for multiple subtypes of T-cell lymphoma[1][2][3][4][6][7].
- Brand names
- Senza5Senza-5Senza 5
- Other names
- CD5-deleted Chimeric Antigen Receptor T cellsCD-5-deleted Chimeric Antigen Receptor T cellsCD 5-deleted Chimeric Antigen Receptor T cellsanti-CD5 CAR T cellsanti-CD-5 CAR T cellsanti-CD 5 CAR T cellsCD5 KO anti-CD5 CAR T cellsCD-5 KO anti-CD5 CAR T cellsCD 5 KO anti-CD5 CAR T cells
02
Targets
CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on VIPER-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIPER-101.